Effects of probiotics, prebiotics and synbiotics on gut microbiota and lipid profiles in patients with dyslipidaemia: A systematic review
Advanced Pharmaceutical Bulletin · 25.07.2026
DOI: 10.34172/apb.46477 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Advanced Pharmaceutical Bulletin, online erschienen am 25.07.2026. Verfasst von Mohammad Amirul Izzan Amran und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Purpose
This systematic review appraised previous findings to uncover the potential of pro-/ pre-/ synbiotics on regulation of gut microbiota and lipid profiles of patients with dyslipidaemia or cardiovascular diseases (CVD).
Method
The literature search was performed using PubMed, Scopus, ScienceDirect and the Cochrane Library. Studies were shortlisted based on the inclusion and exclusion criteria and evaluated for risk of bias using the "RoB 2" tool and the NIH quality assessment tool for before-after (Pre-Post) studies with no control group. Due to heterogeneity, a narrative synthesis was performed.
Results
21 publications were shortlisted, including parallel, crossover and pre-post designs. Most studies were high risk of bias (n=17). Synbiotic interventions (low risk studies from a single trial) demonstrated significant changes in gut microbiota, including increased Bacteroidetes and Bifidobacterium spp., alongside an increase in high-density lipoprotein cholesterol (HDL-C). Pro-/ and prebiotic interventions were also associated with increases in beneficial taxa (Bifidobacterium spp., Faecalibacterium spp., Lactobacillus spp.) and improvements in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). However, with gut microbiota diversity and composition as the primary outcome, findings were inconclusive with most studies presenting high risk of bias due to considerable heterogeneity in study designs, interventions, and microbiota assessment methods.
Conclusion
Evidence from this review remains inconclusive regarding the potential of microbiota-targeted therapies (pro-/ pre-/ and synbiotic) towards dyslipidaemia or CVD due to considerable heterogeneity in microbiota assessment, interventions, study designs and predominance of high risk of bias throughout the studies. This highlights the importance of well-designed and standardised clinical trials.
Zitieren
APA
Amran, M. A. I., Lim, S. M., Neoh, C. F., Majeed, A. B. A., Ramli, A. S., & Ramasamy, K. (2026). Effects of probiotics, prebiotics and synbiotics on gut microbiota and lipid profiles in patients with dyslipidaemia: A systematic review. Advanced Pharmaceutical Bulletin. https://doi.org/10.34172/apb.46477
Vancouver
Amran MAI, Lim SM, Neoh CF, Majeed ABA, Ramli AS, Ramasamy K. Effects of probiotics, prebiotics and synbiotics on gut microbiota and lipid profiles in patients with dyslipidaemia: A systematic review. Advanced Pharmaceutical Bulletin. 2026. doi:10.34172/apb.46477
BibTeX
@article{Amran2026,
author = {Amran, Mohammad Amirul Izzan and Lim, Siong Meng and Neoh, Chin Fen and Majeed, Abu Bakar Abdul and Ramli, Anis Safura and Ramasamy, Kalavathy},
title = {Effects of probiotics, prebiotics and synbiotics on gut microbiota and lipid profiles in patients with dyslipidaemia: A systematic review},
journal = {Advanced Pharmaceutical Bulletin},
year = {2026},
doi = {10.34172/apb.46477}
}
EUVIMED